MIT scientists modified lipids used in experimental mRNA vaccines; the formulations remained stable for up to a year at room temperature and triggered immune responses in mice

Economic Times - Nov 20, 2026

MIT researchers have developed groundbreaking mRNA vaccines that remain effective at higher temperatures, ensuring better distribution, especially in regions lacking adequate ultra-low temperature storage. The use of AI technology has drastically improved the efficiency of vaccine discovery and formulation. Early tests in mice show promising results; however, human trials remain essential for regulatory approval. This innovation promises to enhance vaccine accessibility during future public health emergencies.

Read full article
More News
Copyright © 2015 - 2026 The Financial Capital.

All Rights Reserved.

Subscribe Now!

About Us

The Financial Capital is your independent source for finance information and advice. We provide insights and offer advice from financial experts so you can make the best decisions.